The FDA has asked all manufacturers to immediately withdraw prescriptions and over the counter ranitidine products from the market due to excess levels of NDMA, a probable carcinogen created in the drug. NDMA levels increase in ranitidine even under normal storage and it significantly increases when stored at higher temperatures, including temperatures the product is exposed to during distribution and handling by consumers. The older the ranitidine product is, the higher the levels of NDMA.
If you have taken Zantac or another drug that contains ranitidine and were diagnosed with cancer, contact The Law Firm of Richard M. Lewis, LLC, at our office or www.richardmlewis.com.